FDA approves Novoste's 60mm radiation source:
This article was originally published in Clinica
Executive Summary
The US FDA has given Novoste the green light to market its Beta-Cath system with a longer 60mm radiation source, which is suitable for the treatment of long, diffuse in-stent restenosis. Patients with diffuse, in-stent restenosis typically have the worst clinical outcomes due to the complexity of their disease, says the Atlanta, Georgia firm. The Beta-Cath product line already includes 30-mm and 40mm radiation source lengths.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.